- Home
- PCF vs ANIK Comparison
PCF vs ANIK Comparison
Compare PCF & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCF
- ANIK
- Stock Information
- Founded
- PCF 1987
- ANIK 1983
- Country
- PCF United States
- ANIK United States
- Employees
- PCF N/A
- ANIK N/A
- Industry
- PCF Trusts Except Educational Religious and Charitable
- ANIK Medical/Dental Instruments
- Sector
- PCF Finance
- ANIK Health Care
- Exchange
- PCF Nasdaq
- ANIK Nasdaq
- Market Cap
- PCF 196.9M
- ANIK 196.6M
- IPO Year
- PCF N/A
- ANIK 1993
- Fundamental
- Price
- PCF $5.99
- ANIK $14.04
- Analyst Decision
- PCF
- ANIK Buy
- Analyst Count
- PCF 0
- ANIK 2
- Target Price
- PCF N/A
- ANIK $22.00
- AVG Volume (30 Days)
- PCF 74.8K
- ANIK 72.3K
- Earning Date
- PCF 01-01-0001
- ANIK 05-07-2025
- Dividend Yield
- PCF 10.90%
- ANIK N/A
- EPS Growth
- PCF N/A
- ANIK N/A
- EPS
- PCF N/A
- ANIK N/A
- Revenue
- PCF N/A
- ANIK $119,907,000.00
- Revenue This Year
- PCF N/A
- ANIK N/A
- Revenue Next Year
- PCF N/A
- ANIK $8.72
- P/E Ratio
- PCF N/A
- ANIK N/A
- Revenue Growth
- PCF N/A
- ANIK N/A
- 52 Week Low
- PCF $5.71
- ANIK $12.83
- 52 Week High
- PCF $6.96
- ANIK $29.12
- Technical
- Relative Strength Index (RSI)
- PCF 33.08
- ANIK 41.28
- Support Level
- PCF $5.96
- ANIK $13.29
- Resistance Level
- PCF $6.35
- ANIK $14.73
- Average True Range (ATR)
- PCF 0.17
- ANIK 0.95
- MACD
- PCF -0.03
- ANIK 0.05
- Stochastic Oscillator
- PCF 29.07
- ANIK 46.03
About PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective primarily by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.